Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Maxcyte Inc
(NQ:
MXCT
)
3.670
-0.210 (-5.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
292,131
Open
3.880
Bid (Size)
3.650 (3)
Ask (Size)
3.950 (1)
Prev. Close
3.880
Today's Range
3.655 - 3.910
52wk Range
2.765 - 5.545
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
September 16, 2024
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
September 05, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Performance
YTD
-26.60%
-26.60%
1 Month
-4.18%
-4.18%
3 Month
-12.20%
-12.20%
6 Month
-11.57%
-11.57%
1 Year
+21.93%
+21.93%
More News
Read More
MaxCyte Earnings Preview
March 11, 2024
Via
Benzinga
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 06, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
July 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
May 29, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 22, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 08, 2024
Via
Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
May 08, 2024
Via
Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 08, 2024
Via
Benzinga
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
May 07, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
March 20, 2024
Via
Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
March 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
March 13, 2024
Via
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 12, 2024
Via
Benzinga
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 12, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 04, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For March 12, 2024
March 12, 2024
Via
Benzinga
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
January 30, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.